Patent ID: 8088589

Claim:
An assay for determining if a patient diagnosed with lung cancer is likely to respond to therapeutic treatment with an EGFR-TK inhibitor selected from gefitinib or erlotinib, comprising (a) obtaining a biological sample of tumor tissue or tumor cells from said patient; (b) determining expression levels in said biological sample of the following proteins: p70S6K, comprising the amino acid sequence of SEQ ID NO. 17, phospho-S6 comprising the amino acid sequence of SEQ ID NO. 18, phospho-AKT comprising the amino acid sequence of SEQ ID NO. 19, phospho-mTOR comprising the amino acid sequence of SEQ ID NO. 20, phospho-pTEN comprising the amino acid sequence of SEQ ID NO. 21, EGFR comprising the amino acid sequence of SEQ ID NO. 25, phospho-ER comprising the amino acid sequence of SEQ ID NO. 27, phospho-AR comprising the amino acid sequence of SEQ ID NO. 28, AIK comprising the amino acid sequence of SEQ ID NO. 29, osteopontin comprising the amino acid sequence of SEQ ID NO. 30, MMP11 comprising the amino acid sequence SEQ ID NO. 31 and GFAP comprising the amino acid sequence of SEQ ID NO. 32; and (c) comparing the expression levels in step (b) to expression levels of the same proteins in normal tissue or cells, wherein the patient is a responder to treatment with an EGFR-TK inhibitor if the level of the p70S6K, phospho-S6, phospho-AKT, phospho-mTOR, phospho-pTEN, EGFR, phospho-ER, phospho-AR, AIK, osteopontin, MMP11 and GFAP is up-regulated in the tissue or cells from said biological sample as compared to said normal tissue or cells.